Ipsen
Tracked across 4 events · 35 articles · First seen Jan 29, 2026 · Last active Mar 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Ipsen announced the co-optation of Peter Guenter to its Board of Directors, filling a vacancy and maintaining the board's composition. This appointment is expected to bring valuable experience to Ipsen's leadership.
Jan 29, 2026 · 7 articles
Business
Ipsen is voluntarily withdrawing its drug Tazverik from all markets due to safety concerns identified in the SYMPHONY-1 trial. This decision, while disappointing, is not expected to impact Ipsen's financial guidance. Ipsen's stock price declined by 5.57% on the Frankfurt Stock Exchange following the announcement.
Mar 09, 2026 · 11 articles
Business
Ipsen appointed Michelle C. Werner as Executive Vice President and President of North America, a move expected to accelerate the growth of its portfolio in rare diseases, oncology, and neurosciences. This appointment is part of Ipsen's ongoing transformation and aims to strengthen its presence in the United States market.
Mar 12, 2026 · 7 articles
Tech
Ipsen announced positive preclinical data for its investigational medicines IPN01203 and IPN60300, which could enhance its pipeline and future market position in oncology. This news reinforces Ipsen's precision medicine approach and its potential to address unmet needs in solid tumors.
Mar 18, 2026 · 10 articles
Peter Guenter
Board Director
↔
Ipsen
Peter Guenter was co-opted as a Director to the Board of Ipsen.
NEWSDESK
Track Ipsen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard